Skip to content

SW · LONN.SW · MEDICAL - DIAGNOSTICS & RESEARCH

Lonza Group AG (LONN.SW) intrinsic value and stock valuation

$651.20as of 2026-11-21 · Mkt cap 34.73B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lonza Group AG DCF and intrinsic value

InvestorsCraft values LONN.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LONN.SW’s statements →

Lonza Group AG Graham Number

Graham Number: $199.57d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Basel 4002 lonza.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$6.53B+7.7% 5y CAGRd
20112025
Net income
$949M+1.8% 5y CAGRd
20112025
Free cash flow
-$-204M
20112025
Total equity
$9.19B+5.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$6.53B$6.57B$6.72B$6.22B$5.41B
Operating income$1.38B$964M$880M$1.54B$851M
Net income$949M$636M$654M$1.22B$2.94B
EPSd$13.5M$8.92M$8.88M$16.3M$39.5M
Operating cash flow$1.17B$1.27B$1.39B$1.04B$1.22B
Capital expenditure-$-1.37B-$-1.42B-$-1.65B-$-1.87B-$-1.35B
Free cash flow-$-204M-$-143M-$-263M-$-833M-$-126M
Total assets$19B$19.7B$16.8B$17.4B$16.5B
Total debt$4.19B$5.12B$3.13B$2.59B$2.75B
Net debt$3.47B$4.01B$1.66B$1.25B$1.17B
Total equity$9.19B$9.39B$9.51B$10.7B$9.82B
Cash and short-term investments$719M$1.71B$1.67B$2.22B$3.18B
Income statement
20252024202320222021
Revenue$6.53B$6.57B$6.72B$6.22B$5.41B
Cost of revenue$4.22B$4.41B$4.77B$3.79B$3.3B
Gross profit$2.31B$2.16B$1.95B$2.44B$2.11B
Research and development expenses$0.00$0.00$105M$95M$90M
Selling, general and administrative expenses$765M$945M$837M$827M$754M
Other expenses$186M$251M$126M-$-25M$415M
Operating expenses$951M$1.2B$1.07B$897M$1.26B
Cost and expenses$5.16B$5.61B$5.84B$4.68B$4.56B
Interest income$42M$40M$38M$6M$3M
Interest expense$162M$155M$108M$73M$72M
Depreciation and amortization$47M$647M$621M$596M$522M
Ebitda$1.31B$1.54B$1.53B$2.12B$1.38B
Operating income$1.38B$964M$880M$1.54B$851M
Total other income/expenses, net-$-281M-$-210M-$-90M-$-93M-$-91M
Income before tax$1.1B$754M$790M$1.45B$760M
Income tax expense$192M$117M$135M$230M$83M
Net income$949M$636M$654M$1.22B$2.94B
Weighted average shares outstanding$70.2M$71.2M$73.7M$74.2M$74.3M
Weighted average diluted shares outstanding$70.2M$71.3M$73.7M$74.4M$74.5M
Balance sheet
20252024202320222021
Cash and short-term investments$719M$1.71B$1.67B$2.22B$3.18B
Net receivables$1.78B$1.57B$1.43B$1.49B$1.14B
Inventory$1.68B$1.73B$1.59B$1.82B$1.5B
Total current assets$8B$5.44B$4.9B$5.71B$5.93B
Property, plant and equipment, net$8.3B$8.53B$6.62B$6.12B$4.69B
Goodwill and intangible assets$2.29B$5.37B$4.74B$7.96B$8.43B
Long-term investments$0.00$264M$305M$298M$281M
Total non-current assets$11B$14.3B$12.2B$11.6B$10.5B
Total assets$19B$19.7B$16.8B$17.4B$16.5B
Accounts payable$0.00$406M$468M$477M$483M
Short-term debt$309M$512M$227M$732M$219M
Deferred revenue$0.00$0.00$745M$649M$667M
Total current liabilities$3.57B$3.58B$2.76B$3.08B$2.37B
Long-term debt$3.88B$4.61B$2.91B$1.86B$2.53B
Deferred revenue, non-current$0.00$1.01B$658M$739M$675M
Total non-current liabilities$6.21B$6.77B$4.57B$3.61B$4.27B
Capital lease obligations$0.00$410M$331M$355M$346M
Total liabilities$9.78B$10.3B$7.34B$6.69B$6.64B
Common stock$70M$72M$74M$74M$74M
Retained earnings$9.92B$9.49B$9.49B$9.04B$7.98B
Accumulated other comprehensive income (loss)-$-1.8B-$-1.28B-$-1.5B-$-987M-$-815M
Total equity$9.19B$9.39B$9.51B$10.7B$9.82B
Total investments$0.00$864M$505M$1.18B$1.88B
Total debt$4.19B$5.12B$3.13B$2.59B$2.75B
Net debt$3.47B$4.01B$1.66B$1.25B$1.17B
Cash flow statement
20252024202320222021
Net income$949M$636M$654M$1.22B$674M
Depreciation and amortization$0.00$0.00$621M$596M$522M
Stock-based compensation$0.00$0.00$21M$32M$45M
Change in working capital-$-384M-$-200M$1M-$-581M-$-278M
Accounts receivable$0.00-$-108M-$-35M-$-252M-$-292M
Inventory$0.00$0.00$143M-$-343M-$-381M
Accounts payable$0.00$3M-$-6M-$-2M$213M
Net cash provided by operating activities$1.17B$1.27B$1.39B$1.04B$1.22B
Investments in property, plant and equipment-$-1.37B-$-1.38B-$-1.68B-$-1.87B-$-1.35B
Acquisitions, net-$-56M-$-1.07B-$-93M$235M$72M
Net cash used for investing activities-$-732M-$-2.92B-$-1.1B-$-991M$1.02B
Common stock issued$11M$9M$9M$7M$0.00
Common stock repurchased-$-518M-$-769M-$-1.02B-$-58M-$-174M
Dividends paid-$-280M-$-288M-$-260M-$-223M-$-225M
Net cash used for financing activities-$-755M$1.28B-$-152M-$-286M-$-1.28B
Net change in cash-$-392M-$-357M$129M-$-243M$963M
Cash at end of period$719M$1.11B$1.47B$1.34B$1.58B
Operating cash flow$1.17B$1.27B$1.39B$1.04B$1.22B
Capital expenditure-$-1.37B-$-1.42B-$-1.65B-$-1.87B-$-1.35B
Free cash flow-$-204M-$-143M-$-263M-$-833M-$-126M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lonza Group AG

        Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

        CEO
        Wolfgang Wienand
        Employees
        18K
        Beta
        0.82

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Lonza Group AG (LONN.SW)?

        InvestorsCraft does not currently publish an intrinsic value for LONN.SW. How the IC value is calculated.

        Is LONN.SW undervalued?

        InvestorsCraft does not publish an undervaluation signal for LONN.SW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.